UCB (
Union chimique belge) is a
multinational biopharmaceutical company headquartered in
Brussels, Belgium. UCB is an international company with revenues of €3.3 billion that focuses primarily on R&D, specifically involving medications centered on Epilepsy, Parkinson's, & Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of
central nervous system (CNS) disorders (including
epilepsy),
inflammatory disorders (including
allergy), and
oncology.